The 4 bullish analyst ratings for First Wave BioPharma indicate a positive outlook on the stock. However, the average 12-month price target has decreased by 25% from the previous average, suggesting that analysts have lowered their expectations for the stock's performance. This could lead to a neutral short-term impact on the stock price, as the positive sentiment is counterbalanced by the lowered price target.